Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome) Latest Advances

Find the Latest Research About Mucopolysaccharidosis Type 2 (MPS II, Hunter Syndrome)

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 1423 publications

First-in-class blood-brain barrier shuttle wins FDA nod for Hunter syndrome.

First-in-class blood-brain barrier shuttle wins FDA nod for Hunter syndrome.

Journal: Nature reviews. Drug discovery

Published: March 28, 2026

An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II.

An Intravenous Brain-Penetrant Enzyme Therapy for Mucopolysaccharidosis II.

Journal: The New England journal of medicine

Published: December 30, 2025

Breaking Barriers in Mucopolysaccharidosis Type II.

Breaking Barriers in Mucopolysaccharidosis Type II.

Journal: The New England journal of medicine

Published: December 30, 2025

Intravenous Delivery of a Gene Therapy Vector that Expresses an Antitransferrin Receptor 1 Nanobody-I2S Fusion Protein Rescued Central Nervous System Lysosomal Burden in Mucopolysaccharidosis II Mice.

Intravenous Delivery of a Gene Therapy Vector that Expresses an Antitransferrin Receptor 1 Nanobody-I2S Fusion Protein Rescued Central Nervous System Lysosomal Burden in Mucopolysaccharidosis II Mice.

Journal: Human gene therapy

Published: December 29, 2025

Neurophysiological Characteristics of Upper Extremity Neuropathy in Three Young Patients with Mucopolysaccharidosis Type I and II in a Five-Year Observation-A Case Series Study.

Neurophysiological Characteristics of Upper Extremity Neuropathy in Three Young Patients with Mucopolysaccharidosis Type I and II in a Five-Year Observation-A Case Series Study.

Journal: Neurology international

Published: December 19, 2025

Postoperative subaxial Bow Hunter's syndrome: A rare case triggered by upright posture.

Postoperative subaxial Bow Hunter's syndrome: A rare case triggered by upright posture.

Journal: Surgical neurology international

Published: November 28, 2025

Cerebrospinal fluid heparan sulfate as a biomarker for neuronopathic mucopolysaccharidoses: Rationale and regulatory challenges.

Cerebrospinal fluid heparan sulfate as a biomarker for neuronopathic mucopolysaccharidoses: Rationale and regulatory challenges.

Journal: Molecular genetics and metabolism

Published: November 26, 2025

Safety, tolerability, and pharmacokinetics of verenafusp alfa in healthy volunteers: results of an open-label multicohort phase I study

Safety, tolerability, and pharmacokinetics of verenafusp alfa in healthy volunteers: results of an open-label multicohort phase I study

Journal: Terapevticheskii arkhiv

Published: November 19, 2025

Anaesthetic management of a preadolescent child with Mucopolysaccharidosis type II (Hunter's syndrome) for insertion of a ventriculoperitoneal shunt.

Anaesthetic management of a preadolescent child with Mucopolysaccharidosis type II (Hunter's syndrome) for insertion of a ventriculoperitoneal shunt.

Journal: BMJ case reports

Published: November 04, 2025

The Critical Role of Fractionated Urine Glycosaminoglycans in the Evaluation of Mucopolysaccharidosis Type II in Four Unrelated Families.

The Critical Role of Fractionated Urine Glycosaminoglycans in the Evaluation of Mucopolysaccharidosis Type II in Four Unrelated Families.

Journal: American journal of medical genetics. Part A

Published: October 31, 2025

Peripapillary Scleral Deposits in Mucopolysaccharidosis Type II.

Peripapillary Scleral Deposits in Mucopolysaccharidosis Type II.

Journal: Ophthalmology

Published: October 09, 2025

Knowledge, attitudes, and practices toward linezolid-serotonergic drug interactions: a cross-sectional study.

Knowledge, attitudes, and practices toward linezolid-serotonergic drug interactions: a cross-sectional study.

Journal: Frontiers in pharmacology

Published: October 09, 2025

Showing 1-12 of 1,423

Last Updated: 04/28/2026